Potential influence of international harmonization of pharmaceutical regulations on biopharmaceutical development

被引：6

作者：

Lubiniecki, AS

机构：

[1] SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406-0939, PO Box 1539

来源：

关键词：

D O I：

10.1016/S0958-1669(97)80016-X

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

[No abstract available]

引用

页码：350 / 356

页数：7

共 29 条

[1]

[Anonymous], 1982, MMWR-MORBID MORTAL W, V31, P652

[2]

[Anonymous], POINTS CONS PROD TES

[3]

BROWN F, 1994, GENETIC STABILITY RE

[4] GENETIC STABILITY AND RECOMBINANT PRODUCT CONSISTENCY [J].

BURSTYN, D ;

COPMANN, T ;

DINOWITZ, M ;

GARNICK, R ;

LOSIKOFF, A ;

LUBINIECKI, A ;

WIEBE, M .

[5]

BURSTYN D, 1991, BIOPHARM, V4, P25

[6]

Burstyn DG, 1996, DEV BIOL STAND, V88, P199

[7]

*CDC, 1985, MMWR-MORBID MORTAL W, V34, P1

[8]

CHIU YYH, 1994, DEV BIOL STAND, V83, P93

[9]

*COMM EUR COMM, 1991, VAL VIR REM IN PROC

[10]

*COMM EUR COMM, 1991, MED PROD DER HUM BLO